Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.

Autor: Aldoss I; Division of Leukemia, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Roloff GW; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL., Faramand R; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL., Kopmar NE; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA., Lin C; Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC., Advani AS; Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, OH., Dekker SE; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA.; Division of Hematology-Oncology, Oregon Health Science, Portland, OR., Gupta VK; Division of Hematology & Oncology, University of California, Los Angeles, CA., O'Connor TE; Division of Hematology/Oncology, Loyola University Medical Center, Maywood, IL., Jeyakumar N; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Muhsen IN; Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX., Valtis Y; Department of Hematology and Oncology, Memorial Sloan Kettering Cancer Institute, New York, NY., Zhang A; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Miller K; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Sutherland K; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Dykes KC; Department of Medicine, Division of Hematology and Oncology, University of California, San Diego, CA., Ahmed M; Department of Hematology and Oncology, Cedars Sinai Medical Center, Los Angeles, CA., Chen E; Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA., Zambrano H; Department of Transplant and Cellular Therapy, Sarah Cannon Cancer Institute, Tampa, FL., Bradshaw D; Department of Medicine, Division, Hematology and Oncology, Georgia Cancer Center at Augusta University, Augusta, GA., Mercadal S; Transplant and Cellular Therapy Program, University of Utah, Huntsman Cancer Hospital, Salt Lake, UT., Schwartz M; Department of Hematology and Oncology, University of Colorado, Anschutz Medical Center, Aurora, CO., Tracy S; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN., Dholaria B; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN., Kubiak M; Department of Medicine, Division, Hematology and Oncology, Georgia Cancer Center at Augusta University, Augusta, GA., Mukherjee A; Department of Hematology and Oncology, Oncology Hematology Care, Cincinnati, OH., Majhail N; Department of Transplant and Cellular therapy, Sarah Cannon Cancer Institute, Nashville, TN., Battiwalla M; Department of Transplant and Cellular therapy, Sarah Cannon Cancer Institute, Nashville, TN., Mountjoy L; Department of Lymphoma, Colorado Blood Cancer Institute, Denver, CO., Malik SA; Center for Blood Cancer and Oncology, Texas Transplant Institute, Austin, TX., Mathews J; Department of Transplant and Cellular Therapy, Sarah Cannon Cancer Center, Midland, TX., Shaughnessy P; Department of Transplant and Cellular Therapy, Sarah Cannon Cancer Center, San Antonio, TX., Logan AC; Department of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, CA., Ladha A; Department of Hematology, University of Southern California, Los Angeles, CA., Stefan M; Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, OH., Guzowski C; Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA., Hoeg RT; Department of Internal Medicine, Division of Hematology and Oncology, University of California, Davis, CA., Hilal T; Division of Hematology and Medical Oncology, Mayo Clinic, Rochester, MN., Moore J; Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, NY., Connor M; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA., O'Dwyer KM; Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, NY., Hill LC; Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX., Tsai SB; Division of Hematology/Oncology, Loyola University Medical Center, Maywood, IL., Sasine J; Department of Hematology and Oncology, Cedars Sinai Medical Center, Los Angeles, CA., Solh MM; Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA., Lee CJ; Transplant and Cellular Therapy Program, University of Utah, Huntsman Cancer Hospital, Salt Lake, UT., Kota VK; Department of Medicine, Division, Hematology and Oncology, Georgia Cancer Center at Augusta University, Augusta, GA., Koura D; Department of Medicine, Division of Hematology and Oncology, University of California, San Diego, CA., Veeraputhiran M; Department of Hematology and Oncology, University of Arkansas Medical Center, Little Rock, AR., Blunk B; Department of Transplant and Cellular therapy, Sarah Cannon Cancer Institute, Nashville, TN., Oliai C; Division of Hematology & Oncology, University of California, Los Angeles, CA., Leonard JT; Division of Hematology-Oncology, Oregon Health Science, Portland, OR., Frey NV; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA., Park JH; Department of Hematology and Oncology, Memorial Sloan Kettering Cancer Institute, New York, NY., Luskin MR; Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA., Bachanova V; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN., Galal A; Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC., Bishop MR; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL., Stock W; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL., Cassaday RD; Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA., Pullarkat V; Division of Leukemia, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Shah BD; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL., Muffly LS; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA.

Publikováno v: Blood advances [Blood Adv] 2024 Dec 10; Vol. 8 (23), pp. 6139-6147.

JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results.

Autor: Pidala J; Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Holtan SG; Division of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Walton K; Division of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Kim J; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Cao B; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Elmariah H; Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Mishra A; Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Bejanyan N; Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Nishihori T; Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Khimani F; Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Perez L; Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Faramand RG; Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Davila ML; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY., McSain S; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY., Pleskow J; Department of Pharmacy, Roswell Park Comprehensive Cancer Center, Buffalo, NY., Baron J; Department of Pharmacy, Roswell Park Comprehensive Cancer Center, Buffalo, NY., Anasetti C; Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Moran Segura C; Advanced Analytical and Digital Laboratory, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Weisdorf DJ; Division of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Blazar BR; Division of Pediatric Blood and Marrow Transplantation and Cellular Therapy, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Miller JS; Division of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Bachanova V; Division of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, MN., El Jurdi N; Division of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Betts BC; Division of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, MN.

Publikováno v: Blood [Blood] 2024 Nov 28; Vol. 144 (22), pp. 2295-2307.

Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.

Autor: Roloff GW; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL., Aldoss I; Division of Leukemia, Department of Hematology and Hematopoitic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Kopmar NE; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA., Lin C; Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC., Dekker SE; Division of Hematology-Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Gupta VK; Division of Hematology & Oncology, University of California Los Angeles, Los Angeles, CA., O'Connor TE; Division of Hematology/Oncology, Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, IL., Jeyakumar N; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA., Muhsen IN; Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX., Valtis Y; Memorial Sloan Kettering Cancer Center, New York, NY., Ahmed N; Memorial Sloan Kettering Cancer Center, New York, NY., Zhang A; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA., Miller K; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA., Dykes KC; Department of Medicine, Division of Hematology and Oncology, University of California San Diego Moores Cancer Center, San Diego, CA., Ahmed M; Cedars-Sinai Medical Center, Los Angeles, CA., Chen EC; Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA., Mercadal S; Transplant and Cellular Therapy Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT., Schwartz M; University of Colorado Anschutz School of Medicine, Aurora, CO., Tracy SI; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN., Dholaria B; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN., Mukherjee A; University of Arkansas Medical Center, Little Rock, AK., Battiwalla M; Sarah Cannon Transplant and Cell Therapy Network, Nashville, TN., Logan AC; Department of Medicine, Division of Hematology and Blood and Marrow Transplantation, University of California, San Francisco, CA., Ladha A; Department of Hematology, Norris Cancer Center, University of Southern California, Los Angeles, CA., Guzowski C; Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA., Hoeg RT; Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA., Hilal T; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ., Moore J; Division of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY., Connor MP; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA., Hill LC; Center for Cell and Gene Therapy, Baylor College of Medicine and Houston Methodist Hospital, Houston, TX., Tsai SB; Division of Hematology/Oncology, Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, IL., Sasine JP; Cedars-Sinai Medical Center, Los Angeles, CA., Solh MM; Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA., Kota VK; Georgia Cancer Center, Augusta University, Augusta, GA., Koura D; Department of Medicine, Division of Hematology and Oncology, University of California San Diego Moores Cancer Center, San Diego, CA., Veeraputhiran M; University of Arkansas Medical Center, Little Rock, AK., Leonard JT; Division of Hematology-Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Frey NV; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA., Park JH; Memorial Sloan Kettering Cancer Center, New York, NY., Luskin MR; Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA., Bachanova V; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN., Galal A; Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC., Pullarkat V; Division of Leukemia, Department of Hematology and Hematopoitic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Stock W; Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL., Cassaday RD; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA., Shah BD; Moffitt Cancer Center, Tampa, FL., Faramand R; Moffitt Cancer Center, Tampa, FL., Muffly L; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Oct 17, pp. JCO2400321. Date of Electronic Publication: 2024 Oct 17.

Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation.

Autor: Iqbal M; Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, Florida. Electronic address: Iqbal.madiha@mayo.edu., Kumar A; Department of Internal Medicine, Research Methodology and Biostatistics Core, Office of Research, University of South Florida Morsani College of Medicine, Tampa, Florida., Dreger P; Department of Medicine V, University of Heidelberg, Heidelberg, Germany., Chavez J; Moffitt Cancer Center, Tampa, Florida., Sauter CS; Division of Hematology and Oncology, Cleveland Clinic, Cleveland, Ohio., Sureda AM; Department of Hematology, Institut Català d'Oncologia (ICO), 08908 L'Hospitalet de Llobregat, Barcelona, Spain., Bachanova V; University of Minnesota, Minneapolis, Minnesota., Maziarz RT; Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon., Dreyling M; Department of Internal Medicine III, LMU University Hospital, LMU Munich, Munich, Germany., Smith SM; Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois., Jacobson C; Dana-Farber Cancer Institute, Boston, Massachusetts., Glass B; Klinik für Hämatologie und Stammzelltransplantation, HELIOS Klinikum Berlin-Buch, Berlin, Germany., Casulo C; Department of Hematology/Oncology, University of Rochester, Rochester, New York., Oluwole OO; Vanderbilt University Medical Center, Nashville Tennessee., Montoto S; Department of Haemato-oncology St.Bartholomew's Hospital, Barts Health NHS Trust, London, UK., Advani R; Department of Medicine, Stanford University, Stanford, California., Cohen J; Emory University, Atlanta, Georgia., Salles G; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Hamad N; Department of Haematology, St Vincent's Hospital Sydney, Australia. School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Australia. School of Medicine, Sydney, University of Notre Dame Australia, Sydney, New South Wales, Australia., Kuruvilla J; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Kahl BS; Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri., Shadman M; Fred Hutchinson Cancer Center, Seattle, Washington., Kanate AS; HonorHealth Cancer Transplant Institute, Scottsdale, Arizona., Budde LE; City of Hope National Medical Center, Duarte, California., Kamdar M; University of Colorado Cancer Center, Aurora, Colorado., Flowers C; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hamadani M; CIBMTR/Medical College of Wisconsin, Milwaukee, Wisconsin., Kharfan-Dabaja MA; Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, Florida.

Publikováno v: Transplantation and cellular therapy [Transplant Cell Ther] 2024 Sep; Vol. 30 (9), pp. 832-843. Date of Electronic Publication: 2024 Jul 06.

Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: A multicenter analysis.

Autor: Alsouqi A; Division of Hematology and Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA., Ahmed G; BMT & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Wang J; Division of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Cassanello G; Adult Bone Marrow Transplant Service, Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Department of Oncology and Onco-hematology, University of Milan, Milan, Italy., Szabo A; Division of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Rojek AE; David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, Illinois, USA., Riedell PA; David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, Illinois, USA., Awan F; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA., Samples L; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Shadman M; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Hu M; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA., Bachanova V; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA., Wesson W; Division of Hematologic Malignancies and Cellular Therapy, University of Kansas Cancer Center, Kansas City, Kansas, USA., Ahmed N; Division of Hematologic Malignancies and Cellular Therapy, University of Kansas Cancer Center, Kansas City, Kansas, USA., Iqbal M; Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida, USA., Kharfan-Dabaja MA; Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida, USA., Scordo M; Adult Bone Marrow Transplant Service, Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Johnson PC; Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital - Harvard Medical School, Boston, Massachusetts, USA., Chen YB; Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital - Harvard Medical School, Boston, Massachusetts, USA., Ito S; Division of Hematology and Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA., Hamadani M; BMT & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Frigault M; Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital - Harvard Medical School, Boston, Massachusetts, USA.

Publikováno v: American journal of hematology [Am J Hematol] 2024 Aug; Vol. 99 (8), pp. 1624-1627. Date of Electronic Publication: 2024 May 20.